Barış Erdoğan – CEO, Clinerion
Clinerion, a leader in real-world data solutions, is helping bring medical data informatics to the life sciences industry. CEO Barış Erdoğan explains how the company is creating and applying technology…
Understanding the mechanisms of disease
The Friedrich Miescher Institute is devoted to fundamental biomedical research aimed at understanding the basic molecular mechanisms of health and disease. We communicate and patent our findings to enable their translation into medical application.
The FMI focuses on the fields of
» Epigenetics
» Quantitative Biology
» Neurobiology
In these fields, the FMI has gained international recognition as a center of excellence in innovative biomedical research.
Training young scientists
The Friedrich Miescher Institute contributes to the training of graduate students and postdoctoral fellows. Through its PhD program, which was established as early as 1970, the FMI attracts top international students. The FMI is affiliated with the University of Basel, where most of the graduate students are enrolled and where it contributes to the teaching program. Many FMI alumni have gone on to pursue successful careers in Novartis, in other pharmaceutical companies, or in academic research.
Contact
Friedrich Miescher Institute for Biomedical Research
Maulbeerstrasse 66
4058 Basel
Switzerland
Tel.: +41 61 697 66 51
Clinerion, a leader in real-world data solutions, is helping bring medical data informatics to the life sciences industry. CEO Barış Erdoğan explains how the company is creating and applying technology…
Pius Zängerle of curafutura, one of the two largest Swiss health insurers’ associations, explains the unique Swiss health insurance ecosystem and the main issues on his agenda for 2021 beyond…
A trained physician with several years of practice under her belt, Katharina Gasser then moved into clinical research as an investigator before joining the pharma industry in 2005. Now head…
Alvotech – the biosimilars arm of Icelandic-headquartered generics player Alvogen – is positioning itself for future growth via a very different strategy to that of the Big Pharma players with…
Professor Susan M. Gasser, now director and group leader emeritus of the Friedrich Miescher Institute for Biomedical Research (FMI), shares the crucial aspects behind the FMI’s world-class reputation in basic…
Dr Chris Martin, CEO and co-founder of Swiss-headquartered antibody-drug conjugate cancer company, ADC Therapeutics, shares the company’s journey over the past decade, the exciting progress of their two lead candidates,…
Giorgio Calderari, the chairman of Farma Industria Ticino, the association of chemical and pharmaceutical industries in the Swiss canton of Ticino, explains how a region with a population of 350,000…
The CEO & President of CDMO CordenPharma, Dr Michael Quirmbach, delves into the contract manufacturing industry, explaining the reasons behind the recent commercial success of his organization, including their partnership…
CCO Anil Okay introduces how Alvotech’s focus on biosimilars, comprehensive platform, differentiated portfolio approach, and commercial strategy differentiates the company and allows it to compete with the Big Pharma players…
In an exclusive interview, Jean-Paul Clozel explains Idorsia’s unique value proposition as a biotech focused on small molecules, how agnosticism in terms of therapeutic areas leads to more innovative medical…
AbbVie Switzerland’s Jon Helsdingen outlines how he has led the Swiss affiliate through a full scale office move, the acquisition and integration of Allergan and the COVID-19 pandemic in a…
Mera Pharma’s Khalid Saleh introduces the Swiss-headquartered but MENA-focused company, how it plans to expand via CMOs, and its evolution from food supplements, cosmetics and medical devices into the more…
See our Cookie Privacy Policy Here
